Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

The data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy, which can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition.